DNTH
Dianthus Therapeutics Inc.
88.60$
-2.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
Dianthus Therapeutics Inc. (DNTH) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -49 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.0 | -4.6 | -5.4 | -8.2 | -9.6 | -9.1 | -11 | -13 | -15 | -15 | -12 | -16 | -17 | -19 | -14 | -14 | -17 | -13 | -14 | -16 | -20 | -17 | 16 | -8.9 | -10 | -4.7 | 1.5 | -12 | -15 | -15 | -21 | -27 | -28 | -24 | -31 | -47 | -29 | -49 | -155 | |
| 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 1.2 | 1.2 | 1.2 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.3 | |
| 0.3 | 0.6 | 0.6 | 0.8 | 1.4 | 3.1 | 3.7 | 2.6 | 2.6 | 2.6 | 2.8 | 2.1 | 2.7 | 2.5 | 2.4 | 2.3 | 2.2 | 2.1 | 3.8 | 2.2 | 1.9 | 1.8 | 1.5 | 0.5 | 0.5 | 0.5 | 1.2 | 0.7 | 2.0 | 3.1 | 3.8 | 3.9 | 5.3 | 5.7 | 5.8 | 6.0 | 11 | 12 | 34 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | 0.3 | – | – | 0.2 | 0.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.4 | 1.2 | 0.8 | -1.1 | 0.0 | 1.3 | 1.5 | 1.3 | -2.8 | -0.1 | 6.5 | 5.2 | 0.1 | -3.2 | 0.3 | 1.5 | -2.3 | 1.1 | -1.2 | 0.8 | 0.0 | -2.7 | 0.0 | 1.1 | -3.5 | 6.1 | 10 | -1.6 | -2.8 | 0.3 | 2.6 | -0.4 | -1.7 | 3.1 | 2.9 | 12 | 2.2 | -5.0 | 13 | |
| 0.6 | 0.9 | 0.4 | 0.3 | 0.2 | 0.7 | 2.5 | 4.4 | 1.3 | 1.1 | 0.5 | 0.2 | 0.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | 1.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.3 | |
| -0.7 | -0.9 | -0.4 | -0.3 | -0.2 | -2.5 | -2.5 | -87 | -13 | -44 | 64 | -5.7 | 25 | 15 | 20 | -71 | 7.5 | 30 | 16 | -10 | -40 | -0.1 | -6.9 | -13 | 18 | 22 | -17 | -8.2 | -5.5 | 1.2 | -259 | -23 | 15 | 26 | -201 | 37 | -134 | -479 | -777 | |
| 0.0 | -0.2 | 0.0 | – | 0.0 | -0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -50 | – | – | – | – | 0.3 | 0.1 | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| 6.2 | 63 | 2.0 | – | -0.2 | 144 | -0.7 | -0.5 | 0.6 | 61 | 0.1 | 0.9 | 1.1 | 66 | -0.2 | 1.2 | 0.4 | 89 | 0.2 | 0.1 | 97 | 0.0 | 97 | 0.1 | -16 | 0.0 | 154 | -4.9 | 218 | -2.2 | 0.3 | 40 | 0.2 | 0.6 | 275 | 4.9 | 739 | 10 | 1,029 | |
| 1.5 | 58 | -3.8 | -8.5 | -9.9 | 132 | -14 | -100 | -27 | 1.9 | 52 | -20 | 9.9 | 61 | 5.4 | -84 | -8.9 | 106 | 2.5 | -26 | -60 | -17 | 4.2 | -22 | 7.8 | 17 | 95 | -25 | 197 | -16 | -280 | -11 | -13 | 3.1 | 43 | -4.9 | 577 | -517 | 97 | |
| -4.6 | -5.5 | -5.8 | -8.5 | -9.8 | -9.8 | -13 | -17 | -16 | -16 | -12 | -16 | -17 | -19 | -14 | -14 | -17 | -13 | -15 | -16 | -20 | -17 | 16 | -8.9 | -10 | -4.8 | 1.6 | -12 | -15 | -15 | -21 | -27 | -28 | -24 | -31 | -47 | -29 | -49 | -156 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.